NYSE - Delayed Quote • USD
Edwards Lifesciences Corporation (EW)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:59 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,004,800.00
6,004,800.00
5,382,400.00
5,232,500.00
4,386,300.00
Cost of Revenue
1,379,800.00
1,379,800.00
1,080,400.00
1,248,900.00
1,080,600.00
Gross Profit
4,625,000.00
4,625,000.00
4,302,000.00
3,983,600.00
3,305,700.00
Operating Expense
2,895,200.00
2,895,200.00
2,511,700.00
2,397,100.00
1,989,100.00
Operating Income
1,729,800.00
1,729,800.00
1,790,300.00
1,586,500.00
1,316,600.00
Net Non Operating Interest Income Expense
49,600.00
49,600.00
16,300.00
-1,000.00
7,600.00
Other Income Expense
-181,300.00
-181,300.00
-39,200.00
116,500.00
-407,500.00
Pretax Income
1,598,100.00
1,598,100.00
1,767,400.00
1,702,000.00
916,700.00
Tax Provision
198,700.00
198,700.00
245,500.00
198,900.00
93,300.00
Net Income Common Stockholders
1,402,400.00
1,402,400.00
1,521,900.00
1,503,100.00
823,400.00
Diluted NI Available to Com Stockholders
1,402,400.00
1,402,400.00
1,521,900.00
1,503,100.00
823,400.00
Basic EPS
2.31
--
2.46
2.41
1.32
Diluted EPS
2.30
--
2.44
2.38
1.30
Basic Average Shares
606,700.00
--
619,000.00
623,300.00
622,600.00
Diluted Average Shares
609,400.00
--
624,200.00
631,200.00
631,900.00
Total Operating Income as Reported
1,534,100.00
1,534,100.00
1,748,500.00
1,690,300.00
897,600.00
Total Expenses
4,275,000.00
4,275,000.00
3,592,100.00
3,646,000.00
3,069,700.00
Net Income from Continuing & Discontinued Operation
1,402,400.00
1,402,400.00
1,521,900.00
1,503,100.00
823,400.00
Normalized Income
1,564,197.20
1,564,197.20
1,555,651.20
1,402,157.39
1,188,167.91
Interest Income
67,200.00
67,200.00
35,500.00
17,400.00
23,400.00
Interest Expense
17,600.00
17,600.00
19,200.00
18,400.00
15,800.00
Net Interest Income
49,600.00
49,600.00
16,300.00
-1,000.00
7,600.00
EBIT
1,615,700.00
1,615,700.00
1,786,600.00
1,720,400.00
932,500.00
EBITDA
1,760,600.00
1,760,600.00
1,926,200.00
1,855,200.00
1,039,700.00
Reconciled Cost of Revenue
1,379,800.00
1,379,800.00
1,080,400.00
1,248,900.00
1,080,600.00
Reconciled Depreciation
144,900.00
144,900.00
139,600.00
134,800.00
107,200.00
Net Income from Continuing Operation Net Minority Interest
1,402,400.00
1,402,400.00
1,521,900.00
1,503,100.00
823,400.00
Total Unusual Items Excluding Goodwill
-184,700.00
-184,700.00
-39,200.00
114,300.00
-406,100.00
Total Unusual Items
-184,700.00
-184,700.00
-39,200.00
114,300.00
-406,100.00
Normalized EBITDA
1,945,300.00
1,945,300.00
1,965,400.00
1,740,900.00
1,445,800.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-22,902.80
-22,902.80
-5,448.80
13,357.39
-41,332.09
12/31/2020 - 3/27/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BSX Boston Scientific Corporation
73.17
-0.12%
DXCM DexCom, Inc.
124.34
-9.91%
MDT Medtronic plc
79.74
+0.62%
SYK Stryker Corporation
335.61
-0.46%
ALGN Align Technology, Inc.
309.02
-0.48%
PODD Insulet Corporation
166.19
+1.23%
SWAV Shockwave Medical, Inc.
330.00
+0.31%
ABT Abbott Laboratories
107.53
+0.63%
ITGR Integer Holdings Corporation
109.58
-1.41%
NARI Inari Medical, Inc.
38.42
+0.92%